These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15221957)

  • 21. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PDGFRA activating mutations in gastrointestinal stromal tumors.
    Heinrich MC; Corless CL; Duensing A; McGreevey L; Chen CJ; Joseph N; Singer S; Griffith DJ; Haley A; Town A; Demetri GD; Fletcher CD; Fletcher JA
    Science; 2003 Jan; 299(5607):708-10. PubMed ID: 12522257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
    Frost MJ; Ferrao PT; Hughes TP; Ashman LK
    Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
    Duensing A; Joseph NE; Medeiros F; Smith F; Hornick JL; Heinrich MC; Corless CL; Demetri GD; Fletcher CD; Fletcher JA
    Cancer Res; 2004 Aug; 64(15):5127-31. PubMed ID: 15289315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma.
    Swick BL; Srikantha R; Messingham KN
    J Cutan Pathol; 2013 Jul; 40(7):623-30. PubMed ID: 23621836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
    Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.
    Subramanian S; West RB; Corless CL; Ou W; Rubin BP; Chu KM; Leung SY; Yuen ST; Zhu S; Hernandez-Boussard T; Montgomery K; Nielsen TO; Patel RM; Goldblum JR; Heinrich MC; Fletcher JA; van de Rijn M
    Oncogene; 2004 Oct; 23(47):7780-90. PubMed ID: 15326474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N; Hirota S
    Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors.
    Nakai M; Hashikura Y; Ohkouchi M; Yamamura M; Akiyama T; Shiba K; Kajimoto N; Tsukamoto Y; Hao H; Isozaki K; Hirai T; Hirota S
    Lab Invest; 2012 Mar; 92(3):451-7. PubMed ID: 22083669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
    J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.